Ocular side effects noted in the three treatment groups
| Dose of ivTA | 4 mg(n = 23) | 6 mg(n = 20) | 8 mg(n = 20) | p Value |
|---|---|---|---|---|
| IOP, intraocular pressure; ivTA, intravitreal triamcinolone; LOCS3, Lens Opacity Classification System III. | ||||
| *Transient vitritis developed after ivTA and resolved without sequelae by week 9. | ||||
| Eyes with maximum IOP >21 mm Hg,n (%) | 9 (39%) | 6 (30%) | 11 (55%) | 0.27 |
| Mean (range) time to IOP rise (weeks) | 9 (4–17) | 8.7 (2–26) | 11.5 (4–26) | |
| Mean number of drugs for glaucoma per eye with IOP >21 mm Hg | 1.8 | 1.8 | 2.5 | 0.16 |
| Eyes still receiving drugs for glaucoma at 6 months, n | 4 | 3 | 9 | 0.05 |
| Phakic eyes, n | 19 | 16 | 12 | |
| Phakic eyes with increase in cataract grade, n (%) | 6/19 (32%) | 7/16 (44%) | 2/12 (17%) | 0.31 |
| Average (SD) increase of cataract grading (LOCS3 chart) per phakic patient | 1.1 (2.1) | 0.8 (1.2) | 0.7 (1.6) | 0.53 |
| Other miscellaneous | Mild vitreous haemorrhage 1/23 (4.3%) | Nil | Transient vitritis* 1/20 (5%) | |